Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abide, adulthood, ambulatory, ameliorate, aspect, asymptomatic, bioavailability, bioengineering, bone, borrowing, Breckenridge, Brexit, centralized, CGL, CMC, compatible, congressional, counterpart, currency, customary, CYSTADANE, dataset, debilitating, deployment, diagnose, dislike, dislocation, distinctive, diversification, dysfunction, estate, exit, expert, fishy, folate, fracture, glycol, Grounded, hampered, hereditary, hypothetical, implicit, infrequent, injection, inventor, jumping, Kingdom, Las, licensee, likewise, magnitude, malware, mildest, misdiagnosed, molecularly, molecule, motor, multisystem, myopia, North, ocular, odor, oral, Overview, paraplegia, Parkway, penetration, phishing, polyethylene, poor, preeminent, purposefully, pyridoxine, ransomware, real, recipient, Recordati, replicable, robust, sc, sequence, skeletal, solution, spectrum, spot, standing, subcutaneously, substrate, taste, tHcy, thrombotic, today, translatable, transsulfuration, trust, Untreated, urgent, vascular, vendor, vision, vitamin
Removed:
addressing, adjunct, aid, altered, appetite, ASL, asparaginase, asparagine, ASS, atypical, Australia, Backsolve, bacterial, Barton, behave, belief, biology, biomarker, blocking, Calithera, cellular, chemotherapeutic, China, chrysanthemi, cognizant, conceived, contingent, contractually, controlled, Conversely, convert, copyright, correlation, deciding, defendant, degrading, depleting, depletion, deprivation, description, destroy, directionally, district, elicit, elicited, ending, enforceable, enhancement, Erwinaze, Erwinia, evidentiary, experimental, expiring, exploit, exploited, Expressway, field, fixed, flexibility, founded, founder, frame, gained, George, Georgiou, glutathione, Guide, Hong, hormone, hybrid, India, inform, intracellular, IPO, Israel, issuable, Kong, Korea, leased, leasehold, lymphoblastic, mechanism, microbial, modulator, MoPac, negotiation, notably, obtainable, occupy, Oncaspar, OPM, OTC, oxidized, paradigm, participated, participating, passionate, patentee, pegaspargase, Plaza, precision, Professor, proliferation, proof, prostate, PWERM, radiation, reclassified, regimen, relate, remeasured, remission, rental, ROS, scenario, sector, seeking, selectively, South, sponsored, SRA, stopped, strategically, strive, studied, suggesting, suit, supportive, Supreme, surgery, synthesize, systemic, tissue, transcarbamoylase, transitioned, uncontrolled, uncured, undistributed, uptake, utility, utilizing, valid, variously, vulnerability, weakened, xenograft
Filing tables
Filing exhibits
Related press release
SYRE similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228967) and Form S-8 (No. 333-210633, 333-216903, 333-223614 and 333-230137) of Aeglea BioTherapeutics, Inc. of our report dated February 24, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
February 24, 2020